SCHEMBL6318588

SCHEMBL6318588

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)C=Cc3ccccc3)cc2c1Cc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 2/20 0.40
SCN9A Q15858 2/20 0.40
MAPT P10636 4/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
PTGS2 P35354 1/20 0.38
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
ESR1 P03372 1/20 0.37
SNCA P37840 1/20 0.36
MCL1 Q07820 4/20 0.36
EGFR P00533 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
TP53 P04637 1/20 0.35
PTPN5 P54829 1/20 0.35
PPARG P37231 1/20 0.35
SCN2B O60939 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319284 1.00 SCN5A (0.40) SCN5ASCN9AMAPTMRGPRX4PTGS2
SCHEMBL5882071 0.89 MAPT (0.42) MAPTPTGS2SNCAMCL1KDM4E
SCHEMBL5882069 0.89 MAPT (0.42) MAPTPTGS2SNCAMCL1KDM4E
SCHEMBL6318339 0.88 SCN5A (0.41) SCN5ASCN9AMAPTMRGPRX4PTGS2
SCHEMBL6135076 0.88 MAPT (0.41) MAPTPTGS2KDM4EMEN1LMNA
SCHEMBL6135073 0.88 MAPT (0.41) MAPTPTGS2KDM4EMEN1LMNA
SCHEMBL5881987 0.88 MAPT (0.42) SCN9AMAPTPTGS2SNCAMCL1
SCHEMBL6322000 0.83 PPARG (0.45) SCN5ASCN9AMRGPRX4EPHX2NR1H4
SCHEMBL6135287 0.83 SCN5A (0.42) SCN5ASCN9AMAPTMRGPRX4PTGS2
SCHEMBL6320424 0.83 SCN5A (0.39) SCN5ASCN9AMAPTMRGPRX4PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
US-6891044-B2 Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2005-05-10 US disclosed
US-6534524-B1 Antiproliferative agents, including axitinib AGOURON PHARMACEUTICALS, INC. 2003-03-18 US disclosed
US-6531491-B1 Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, AGOURON PHARAMACEUTICALS, INC. 2003-03-11 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A SCN5A 59/4885SCN9A 1847/4885MAPT 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.